Mesoblast Ltd
REVASCOR (MPC)
Right Heart Failure (RHF)
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for REVASCOR (MPC) in Right Heart Failure (RHF) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“With the new data, existing Orphan Drug designation for treating this group of patients, and FDA’s stated preference for randomized controlled trials, Mesoblast is moving from filing for accelerated approval to filing for full FDA approval”